Registered title, quoted from ClinicalTrials.gov
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital of Nanchang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07398599, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 99 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC), staged as IV according to the 8th edition of the IASLC TNM classification (2015).
Inclusion criterion 2
At least 21 days since the last radiotherapy (including whole-brain radiotherapy or local radiotherapy for brain metastases).
Inclusion criterion 7
For women: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) within 14 days prior to enrollment, during the study, and for 3 months after the last study drug administration.
Inclusion criterion 10
For men: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) during the study and for 3 months after the last study drug administration.
Inclusion criterion 11
Major surgery within 4 weeks prior to the start of study treatment, or need for major surgery during the study.
Exclusion criterion 1
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Inclusion criterion 5
Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).
Inclusion criterion 3
Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
Exclusion criterion 2
History of other systemic malignant tumors within the past 5 years (except for cured basal cell carcinoma, carcinoma in situ of the cervix, and ovarian cancer).
Exclusion criterion 7
Pregnancy, lactation, or refusal of effective contraception by patients of childbearing potential.
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07398599, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria
- Aged ≥ 18 years at the time of signing the informed consent form, regardless of gender.
- Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC), staged as IV according to the 8th edition of the IASLC TNM classification (2015).
- Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).
- Leptomeningeal metastasis (LM) progression after standard-dose first-, second-, or third-generation EGFR-TKI treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate major organ function, defined as: hemoglobin (Hb) ≥ 90 g/L, absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet count (PLT) ≥ 100 × 10\^9/L, white blood cell count (WBC) ≥ 3.0 × 10\^9/L and ≤ 10.0 × 10\^9/L; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 × ULN; creatinine clearance ≥ 50 ml/min (for patients with liver metastases, TBIL ≤ 3.0 × ULN, ALT and AST ≤ 5.0 × ULN); activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤ 1.5 × ULN.
- At least 21 days since the last radiotherapy (including whole-brain radiotherapy or local radiotherapy for brain metastases).
- Expected survival ≥ 3 months.
- Ability to swallow oral medications (or receive crushed medications via gastrostomy tube if unable to swallow).
- For women: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) within 14 days prior to enrollment, during the study, and for 3 months after the last study drug administration.
- For men: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) during the study and for 3 months after the last study drug administration.
- Voluntary participation, signed informed consent, and willingness to comply with study procedures and protocols.
Exclusion Criteria
- Major surgery within 4 weeks prior to the start of study treatment, or need for major surgery during the study.
- Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- Active bacterial/fungal/viral infections requiring intravenous antibiotic therapy.
- Drug-induced pneumonitis or interstitial lung disease, or evidence of clinically significant active pulmonary disease.
- Severe cardiovascular events within 6 months prior to enrollment, including cerebrovascular accident, deep vein thrombosis, or pulmonary embolism.
- Significant cardiovascular disease, such as New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, symptomatic arrhythmias requiring treatment, or corrected QT interval (QTcF) > 470 ms on consecutive electrocardiograms.
- History of other systemic malignant tumors within the past 5 years (except for cured basal cell carcinoma, carcinoma in situ of the cervix, and ovarian cancer).
- Use of drugs or supplements known to be strong inducers of CYP3A4.
- Known severe allergy to any study drug or its excipients.
- Pregnancy, lactation, or refusal of effective contraception by patients of childbearing potential.
- History of definite neurological or psychiatric disorders (including epilepsy and dementia).
- Other conditions deemed unsuitable for enrollment by the investigator.
Quoted from ClinicalTrials.gov, NCT07398599, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07398599, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.